Analysis: Agilent Technologies, Inc.

US:A

Why is Agilent Technologies, Inc. stock rising?

  • Advanced Therapeutics Train C specialty-CDMO capacity is scheduled to come online in spring 2027, beginning revenue generation at the new facility.
  • Initial U.S. pharma reshoring orders, including five top-10 pharma companies, are expected to start converting into revenue in fiscal 2027.
  • The Altura consumables column family is being expanded into additional biopharma workflows, with further use cases planned in coming quarters.
  • Agilent's new China Innovation Center is starting lab-automation software co-development with a commercial testing customer ahead of a fully automated lab deployment.
  • Biocare's clinically focused antibody menu is being integrated into Agilent's pathology business and is included in the fiscal fourth-quarter revenue guide.

Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Agilent Technologies, Inc. and 4,900+ companies.

Sign in
5-day free pass. No card required.